An overview of PsoProtect’s current data.

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click here to read our scientific research paper detailing the PsoProtect data, entitled ‘Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study‘.

Total number of cases reported

Summary data from PsoProtect’s first 1652 cases.

Cases reported by country of assessment (≥20 cases):
Country Cases
United Kingdom 448
France 308
Italy 175
Spain 138
Netherlands 123
Portugal 71
United States 48
Hungary 51
Poland 78
Argentina 29
Belgium 23
Rest of the world 160

Average age: 48 years
Phenotype of psoriasis: 1605 plaque psoriasis, 47 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days

Confirmed COVID-19:


Smoking history:

Concurrent psoriatic arthritis:

Severity of psoriasis at time of onset of COVID-19 (PGA):

Hospitalization required due to COVID-19:

Systemic medication for psoriasis at time of onset of COVID-19:

Medication Count
Biologic – TNF inhibitor 377
Biologic – IL-23 inhibitor 434
Biologic – IL-17 inhibitor 251
Conventional systemic agent 210
Small molecule inhibitor 57
Biologic and conventional systemic co-therapy 46
Small molecule inhibitor and conventional systemic co-therapy 5
No systemic agent 268
Unknown (participating in clinical trial) 4

Was the biologic medication for psoriasis stopped during COVID-19 infection:

Outcome of COVID-19: